Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials
To evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients. PubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized controlled trial studies from December 2019 to July 2023. A total of 6 randomi...
Gespeichert in:
| Veröffentlicht in: | Saudi medical journal 2024-04, Vol.45 (4), p.341-348 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 348 |
|---|---|
| container_issue | 4 |
| container_start_page | 341 |
| container_title | Saudi medical journal |
| container_volume | 45 |
| creator | Shen, Xiangbo Qiu, Eryue Liu, Zhao Zhu, Xiaopeng Zeng, Yiqian |
| description | To evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients.
PubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized controlled trial studies from December 2019 to July 2023.
A total of 6 randomized controlled trials, which included a total of 3323 patients, were considered for evaluation. Overall, short-term all-cause mortality and hospitalization rates were not significantly different between the rivaroxaban and control groups. Thrombotic events were significantly reduced in the rivaroxaban prophylaxis group compared to the placebo control group. However, the reduction in thrombotic events was not significantly different between rivaroxaban therapy and heparin or low-molecular-weight heparin (LMWH). Rivaroxaban prophylaxis and the therapeutic dose may be associated with a higher rate of overall bleeding rate, but major bleeding rates did not differ substantially.
Rivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding.
. |
| doi_str_mv | 10.15537/smj.2024.45.4.20230728 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11147572</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>38657982</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-e5fd3e324dfd0df2814f29eeb460f362429a5c02c622bab2162a1839af3734753</originalsourceid><addsrcrecordid>eNpVkd1OGzEQRq2qqEnTvkLxC2zwv3e5qaJAaSSk3LS9tWZ3bTDaXUe2iQhXPHpNKKhczSeNvjMjHYROKVlSKbk-S-PdkhEmlkIuxXPiRLP6A5pTJeuKUy0_ojnhuqkkq8UMfU7pjhCuFFGf0IzXSuqmZnP0dOmc7bLf28mmhGHqcQJn8wEHh6PfQwwP0MKEXYhlm30X4OZ-gOzDhPOtjbA7YD_h9fbP5qKizTle4dFmqGCC4ZB8OnIKNoz-0fa4C1OOYRhKzNHDkL6gE1eG_fpvLtDvH5e_1j-r6-3VZr26rjpOZa6sdD23nIne9aR3rKbCscbaVijiuGKCNSA7wjrFWAsto4oBrXkDjmsutOQL9P2Fu7tvR9t3tvwBg9lFP0I8mADevN9M_tbchL2hlJa-ZoWgXwhdDClF697KlJijFVOsmGcrRkgjzKuV0vz2_-233qsG_hdr9IzU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Shen, Xiangbo ; Qiu, Eryue ; Liu, Zhao ; Zhu, Xiaopeng ; Zeng, Yiqian</creator><creatorcontrib>Shen, Xiangbo ; Qiu, Eryue ; Liu, Zhao ; Zhu, Xiaopeng ; Zeng, Yiqian</creatorcontrib><description>To evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients.
PubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized controlled trial studies from December 2019 to July 2023.
A total of 6 randomized controlled trials, which included a total of 3323 patients, were considered for evaluation. Overall, short-term all-cause mortality and hospitalization rates were not significantly different between the rivaroxaban and control groups. Thrombotic events were significantly reduced in the rivaroxaban prophylaxis group compared to the placebo control group. However, the reduction in thrombotic events was not significantly different between rivaroxaban therapy and heparin or low-molecular-weight heparin (LMWH). Rivaroxaban prophylaxis and the therapeutic dose may be associated with a higher rate of overall bleeding rate, but major bleeding rates did not differ substantially.
Rivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding.
.</description><identifier>ISSN: 0379-5284</identifier><identifier>EISSN: 1658-3175</identifier><identifier>DOI: 10.15537/smj.2024.45.4.20230728</identifier><identifier>PMID: 38657982</identifier><language>eng</language><publisher>Saudi Arabia: Saudi Medical Journal</publisher><subject>Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; COVID-19 - complications ; COVID-19 Drug Treatment ; Factor Xa Inhibitors - adverse effects ; Factor Xa Inhibitors - therapeutic use ; Hemorrhage - chemically induced ; Heparin - adverse effects ; Heparin - therapeutic use ; Heparin, Low-Molecular-Weight - adverse effects ; Heparin, Low-Molecular-Weight - therapeutic use ; Humans ; Randomized Controlled Trials as Topic ; Rivaroxaban - adverse effects ; Rivaroxaban - therapeutic use ; SARS-CoV-2 ; Systematic Review ; Thrombosis - etiology ; Thrombosis - prevention & control ; Treatment Outcome</subject><ispartof>Saudi medical journal, 2024-04, Vol.45 (4), p.341-348</ispartof><rights>Copyright: © Saudi Medical Journal.</rights><rights>Copyright: © Saudi Medical Journal 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-7419-6232</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11147572/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11147572/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38657982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shen, Xiangbo</creatorcontrib><creatorcontrib>Qiu, Eryue</creatorcontrib><creatorcontrib>Liu, Zhao</creatorcontrib><creatorcontrib>Zhu, Xiaopeng</creatorcontrib><creatorcontrib>Zeng, Yiqian</creatorcontrib><title>Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials</title><title>Saudi medical journal</title><addtitle>Saudi Med J</addtitle><description>To evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients.
PubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized controlled trial studies from December 2019 to July 2023.
A total of 6 randomized controlled trials, which included a total of 3323 patients, were considered for evaluation. Overall, short-term all-cause mortality and hospitalization rates were not significantly different between the rivaroxaban and control groups. Thrombotic events were significantly reduced in the rivaroxaban prophylaxis group compared to the placebo control group. However, the reduction in thrombotic events was not significantly different between rivaroxaban therapy and heparin or low-molecular-weight heparin (LMWH). Rivaroxaban prophylaxis and the therapeutic dose may be associated with a higher rate of overall bleeding rate, but major bleeding rates did not differ substantially.
Rivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding.
.</description><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>COVID-19 - complications</subject><subject>COVID-19 Drug Treatment</subject><subject>Factor Xa Inhibitors - adverse effects</subject><subject>Factor Xa Inhibitors - therapeutic use</subject><subject>Hemorrhage - chemically induced</subject><subject>Heparin - adverse effects</subject><subject>Heparin - therapeutic use</subject><subject>Heparin, Low-Molecular-Weight - adverse effects</subject><subject>Heparin, Low-Molecular-Weight - therapeutic use</subject><subject>Humans</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Rivaroxaban - adverse effects</subject><subject>Rivaroxaban - therapeutic use</subject><subject>SARS-CoV-2</subject><subject>Systematic Review</subject><subject>Thrombosis - etiology</subject><subject>Thrombosis - prevention & control</subject><subject>Treatment Outcome</subject><issn>0379-5284</issn><issn>1658-3175</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkd1OGzEQRq2qqEnTvkLxC2zwv3e5qaJAaSSk3LS9tWZ3bTDaXUe2iQhXPHpNKKhczSeNvjMjHYROKVlSKbk-S-PdkhEmlkIuxXPiRLP6A5pTJeuKUy0_ojnhuqkkq8UMfU7pjhCuFFGf0IzXSuqmZnP0dOmc7bLf28mmhGHqcQJn8wEHh6PfQwwP0MKEXYhlm30X4OZ-gOzDhPOtjbA7YD_h9fbP5qKizTle4dFmqGCC4ZB8OnIKNoz-0fa4C1OOYRhKzNHDkL6gE1eG_fpvLtDvH5e_1j-r6-3VZr26rjpOZa6sdD23nIne9aR3rKbCscbaVijiuGKCNSA7wjrFWAsto4oBrXkDjmsutOQL9P2Fu7tvR9t3tvwBg9lFP0I8mADevN9M_tbchL2hlJa-ZoWgXwhdDClF697KlJijFVOsmGcrRkgjzKuV0vz2_-233qsG_hdr9IzU</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Shen, Xiangbo</creator><creator>Qiu, Eryue</creator><creator>Liu, Zhao</creator><creator>Zhu, Xiaopeng</creator><creator>Zeng, Yiqian</creator><general>Saudi Medical Journal</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7419-6232</orcidid></search><sort><creationdate>202404</creationdate><title>Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials</title><author>Shen, Xiangbo ; Qiu, Eryue ; Liu, Zhao ; Zhu, Xiaopeng ; Zeng, Yiqian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-e5fd3e324dfd0df2814f29eeb460f362429a5c02c622bab2162a1839af3734753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>COVID-19 - complications</topic><topic>COVID-19 Drug Treatment</topic><topic>Factor Xa Inhibitors - adverse effects</topic><topic>Factor Xa Inhibitors - therapeutic use</topic><topic>Hemorrhage - chemically induced</topic><topic>Heparin - adverse effects</topic><topic>Heparin - therapeutic use</topic><topic>Heparin, Low-Molecular-Weight - adverse effects</topic><topic>Heparin, Low-Molecular-Weight - therapeutic use</topic><topic>Humans</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Rivaroxaban - adverse effects</topic><topic>Rivaroxaban - therapeutic use</topic><topic>SARS-CoV-2</topic><topic>Systematic Review</topic><topic>Thrombosis - etiology</topic><topic>Thrombosis - prevention & control</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shen, Xiangbo</creatorcontrib><creatorcontrib>Qiu, Eryue</creatorcontrib><creatorcontrib>Liu, Zhao</creatorcontrib><creatorcontrib>Zhu, Xiaopeng</creatorcontrib><creatorcontrib>Zeng, Yiqian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Saudi medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shen, Xiangbo</au><au>Qiu, Eryue</au><au>Liu, Zhao</au><au>Zhu, Xiaopeng</au><au>Zeng, Yiqian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials</atitle><jtitle>Saudi medical journal</jtitle><addtitle>Saudi Med J</addtitle><date>2024-04</date><risdate>2024</risdate><volume>45</volume><issue>4</issue><spage>341</spage><epage>348</epage><pages>341-348</pages><issn>0379-5284</issn><eissn>1658-3175</eissn><abstract>To evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients.
PubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized controlled trial studies from December 2019 to July 2023.
A total of 6 randomized controlled trials, which included a total of 3323 patients, were considered for evaluation. Overall, short-term all-cause mortality and hospitalization rates were not significantly different between the rivaroxaban and control groups. Thrombotic events were significantly reduced in the rivaroxaban prophylaxis group compared to the placebo control group. However, the reduction in thrombotic events was not significantly different between rivaroxaban therapy and heparin or low-molecular-weight heparin (LMWH). Rivaroxaban prophylaxis and the therapeutic dose may be associated with a higher rate of overall bleeding rate, but major bleeding rates did not differ substantially.
Rivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding.
.</abstract><cop>Saudi Arabia</cop><pub>Saudi Medical Journal</pub><pmid>38657982</pmid><doi>10.15537/smj.2024.45.4.20230728</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-7419-6232</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0379-5284 |
| ispartof | Saudi medical journal, 2024-04, Vol.45 (4), p.341-348 |
| issn | 0379-5284 1658-3175 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11147572 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Anticoagulants - adverse effects Anticoagulants - therapeutic use COVID-19 - complications COVID-19 Drug Treatment Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - therapeutic use Hemorrhage - chemically induced Heparin - adverse effects Heparin - therapeutic use Heparin, Low-Molecular-Weight - adverse effects Heparin, Low-Molecular-Weight - therapeutic use Humans Randomized Controlled Trials as Topic Rivaroxaban - adverse effects Rivaroxaban - therapeutic use SARS-CoV-2 Systematic Review Thrombosis - etiology Thrombosis - prevention & control Treatment Outcome |
| title | Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T08%3A34%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20safety%20of%20rivaroxaban%20for%20anticoagulation%20therapy%20in%20COVID-19:%20A%20meta-analysis%20of%20randomized%20controlled%20trials&rft.jtitle=Saudi%20medical%20journal&rft.au=Shen,%20Xiangbo&rft.date=2024-04&rft.volume=45&rft.issue=4&rft.spage=341&rft.epage=348&rft.pages=341-348&rft.issn=0379-5284&rft.eissn=1658-3175&rft_id=info:doi/10.15537/smj.2024.45.4.20230728&rft_dat=%3Cpubmed_cross%3E38657982%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/38657982&rfr_iscdi=true |